BICYCLE THERAPEUTICS PLC
BCYCDrugs in Pipeline
8
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
Get an email about BCYC's next catalysts
Track BICYCLE THERAPEUTICS (BCYC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
3 upcoming, 0 past
BCYC Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.30 | FQ end Sep/2026 | Call: tbd
BT5528 Phase 2 Est. Readout
Estimated primary completion for BT5528 trial (NCT04180371) in Advanced Solid Tumor Historically Known for High EphA2 Expression. Topline data typically follows completion by weeks to months.
SourceBT8009 Phase 2 Est. Readout
Estimated primary completion for BT8009 trial (NCT04561362) in Urinary Bladder Neoplasm. Topline data typically follows completion by weeks to months.
SourceGemcitabine + cisplatin Or carboplatin
Metastatic Urothelial Cancer
BT8009
Urinary Bladder Neoplasm
BT7480
Advanced Solid Tumor
nuzefatide pevedotin (BT5528)
Pancreatic Ductal Adenocarcinoma (PDAC)
BT1718
Advanced Solid Tumours
Zelenectide pevedotin (BT8009)
Non-Small Cell Lung Cancer
Zelenectide pevedotin
Non-Small Cell Lung Cancer
BT5528
Advanced Solid Tumor Historically Known for High EphA2 Expression
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gemcitabine + cisplatin Or carboplatin | Phase 3 | Metastatic Urothelial Cancer | - | - |
BT8009 | Phase 3 | Urinary Bladder Neoplasm | - | - |
BT7480 | Phase 2 | Advanced Solid Tumor | - | - |
nuzefatide pevedotin (BT5528) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
BT1718 | Phase 2 | Advanced Solid Tumours | - | - |
Zelenectide pevedotin (BT8009) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Zelenectide pevedotin | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BT5528 | Phase 2 | Advanced Solid Tumor Historically Known for High EphA2 Expression | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BICYCLE THERAPEUTICS PLC's drug pipeline?→
CatalystAlert tracks 8 drug candidates in BICYCLE THERAPEUTICS PLC's (BCYC) pipeline across Phase 3, Phase 2. Its lead program is BT8009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BICYCLE THERAPEUTICS PLC's next FDA catalyst?→
BICYCLE THERAPEUTICS PLC's (BCYC) next tracked catalyst is a Phase 2 readout expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCYC biotech catalysts?→
Add BCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BICYCLE THERAPEUTICS PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.